GOSS
GOSS
NASDAQ · Biotechnology

Gossamer Bio Inc

$9.42
-0.53 (-5.33%)
As of Nov 7, 2:02 AM ET ·
Financial Highlights (FY 2026)
Revenue
109.23M
Net Income
-383,926,522
Gross Margin
—
Profit Margin
-351.5%
Rev Growth
—
D/E Ratio
6.70
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin — 54.6% 54.6% 54.6%
Operating Margin -352.2% 16.7% 17.5% 15.5%
Profit Margin -351.5% 13.7% 12.9% 13.2%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 109.23M 95.94M 101.30M 82.00M
Gross Profit — 52.40M 55.33M 44.79M
Operating Income -384,735,992 16.00M 17.71M 12.71M
Net Income -383,926,522 13.15M 13.02M 10.81M
Gross Margin — 54.6% 54.6% 54.6%
Operating Margin -352.2% 16.7% 17.5% 15.5%
Profit Margin -351.5% 13.7% 12.9% 13.2%
Rev Growth — +8.6% -0.1% -2.0%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 26.38M 246.05M 242.42M 231.61M
Total Equity 3.94M 241.28M 245.05M 267.08M
D/E Ratio 6.70 1.02 0.99 0.87
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -384,679,658 20.01M 19.52M 14.99M
Free Cash Flow — 11.25M 11.45M 12.65M